Table 1 Baseline characteristics of the study groups
Characteristics | Standard care group (n = 791) | R6M group (n = 1166) | p-value for difference between the group | |
|---|---|---|---|---|
Age, mean (SD) years | 40.1 (10.9) | 41.8 (10.8) | 0.0007 | |
Gender, n (%) | ||||
Male | 229 (28.9) | 383 (32.8) | ||
Female | 562 (71.0) | 783 (67.2) | ||
Total | 791 (100) | 1166 (100) | 0.068 | |
Current CD4 count, mean (SD) cells/μl | 497 (261) | 494 (243) | 0.769 | |
Baseline Viral Load for eligibility in copies/μl, n (%) | ||||
< 250 | 741 (93.7) | 1145 (98.2) | ||
250–1000 | 50 (6.3) | 21 (1.8) | ||
Total | 791 (100) | 1166 (100) | < 0.001 | |
TB status at any follow-up visit, n (%) | ||||
Negative/Unknown | 778 (98.4) | 1150 (98.6) | ||
Positive | 13 (1.6) | 16 (1.4) | ||
Total | 791 (100) | 1166 (100) | 0.626 | |
Duration on ART in months, n (%) | ||||
< 60 | 419 (53.9) | 557 (47.8) | ||
≥ 60 | 358 (46.1) | 609 (52.2) | ||
Total | 777 (100) | 1166 (100) | 0.008 | |
TDF-3TC-EFV regimen, n (%) | ||||
No | 366 (46.3) | 202 (17.3) | ||
Yes | 425 (53.7) | 963 (82.7) | ||
Total | 791 (100) | 1165 (100) | <0.001 | |
Outcome, n (%) | ||||
In care | 707 (89.4) | 1109 (95.1) | ||
Lost to Follow-up | 74 (9.4) | 45 (3.9) | ||
Dead | 10 (1.3) | 12 (1.0) | ||
Total | 791 (100) | 1166 (100) | < 0.001 | |